Patients with previously treated advanced neuroendocrine tumors who received treatment with Cabometyx had improved progression-free survival compared with placebo.
Patients with advanced neuroendocrine tumors who experienced progression following prior therapy experienced a significant improvement in terms of progression-free survival after treatment with cabozantinib compared with placebo.
Molecular Tumor Board Aids Cancer Precision Medicine miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
(0) ITM AG, a leading radiopharmaceutical company, today announced that it will host a virtual symposium titled, New Approaches for Targeted Radionuclide Therapy in Precision Oncology as an ancillary event in parallel to the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The symposium will feature renowned key opinion leaders in the field and will be held on Friday, June 4
th, 2021 from 9.30 am 11.00 am ET 3.30 pm 5.00 pm CEST.
The interactive live-session will explore the latest science and clinical practices driving Targeted Radionuclide Therapy to the forefront of the precision oncology field. Participating experts will lead critical examinations and discussions surrounding topics including the current and future potential of Targeted Radionuclide Therapy in cancer therapy and diagnostics, its application in hard-to-treat indications such as gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) and novel developments in the field, including ITM s pro